Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

lio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, ha
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... March 25 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... on Tuesday, April 1st, 2008 at 10:00am EDT to ... the Company., To access the conference call, please ... this conference call is,7767549. Please dial in 5 to ...
... PALO ALTO, Calif., March 25 Varian Medical,Systems (NYSE: VAR ) ... 2008 following the close of regular trading on,Wednesday, April 23, 2008. The ... at 2:00 p.m. PT., , The Varian Medical Systems quarterly results ... Contact Anne Rambo via phone at 650-424-5834 or ...
... Codexis, Inc., today,announced the appointment of David Anton, ... Research and Development. He,joins Codexis from DuPont, where ... Alan Shaw, Ph.D., President and CEO., "Codexis ... technology can make a significant impact," said Alan ...
Cached Biology Technology:Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call 2Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call 3Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call 2Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call 3Codexis Names David Anton VP Bioindustrials R&D 2
(Date:4/24/2014)... Carbon offsetting initiatives could be improved with new insights ... , Scientists studying the Amazon Basin have revealed ... trees across the region by comparing satellite maps with ... enable researchers to assess more accurately the amount of ... factor in carbon offset schemes, in which trees are ...
(Date:4/24/2014)... turtle in North America, weighing in at up to ... from Florida and the University of Vermont have discovered ... , Examining museum specimens and wild turtles, the scientists ... Once heavily hunted for turtle meat alligator snapper ... the 1960s the riverine populations have been deeply ...
(Date:4/24/2014)... out a welcome mat to bacteria seeking to invade, and ... published this week in the Proceedings of the National ... between microbe and host that researchers can exploit to protect ... plant Arabidopsis puts out a molecular signal that ... hostile army were unknowingly passing by a castle, and the ...
Breaking Biology News(10 mins):Amazon rainforest survey could improve carbon offset schemes 2Two new US turtle species described 2Two new US turtle species described 3How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3
... Current arthritis medications can ease the pain, but ... aggressive treatments: use of very limited available drugs ... to find new therapeutic targets for arthritis by ... interrupted, may prevent arthritis pain caused by joint ...
... More than 300 people and 30 companies are expected ... career fair on March 13, 2009 at NJIT. The ... 3:30 p.m. in NJIT,s Campus Center, unites industry professionals ... "Explore the Leading Edge of the ...
... by the Wildlife Conservation Society, have helped the government ... protect more than 600 gorillas, along with other threatened ... Called Deng Deng National Park, the new ... kilometers) in sizeapproximately the size of the City of ...
Cached Biology News:Inhibiting proteins may prevent cartilage breakdown in arthritis patients 2NJIT to host major biomedical engineering showcase and career fair 2Wildlife Conservation Society helps Cameroon create new national park 2Wildlife Conservation Society helps Cameroon create new national park 3
Recombinant Rhesus Monkey IFN-Alpha...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
Biology Products: